In recent studies, numerous biomarkers (e.g., tumor size, lymph node status, Ki-67, HER2, etc.)and imaging-based metrics (e.g., MRI and PET) have been studied for the prediction of pCR and survival (5, 6); however, reliable predictive and prognostic biological markers remain limited. The gene discussed is ERBB2; the disease is neoplasm.